Teladoc (TDOC) Up 3.2% Since Last Earnings Report: Can It Continue?

Core Viewpoint - Teladoc Health reported a narrower adjusted loss in Q4 2025 compared to the previous year, driven by international growth and lower costs, but faced challenges from declining U.S. revenues and the BetterHelp segment [3][4][5]. Financial Performance - Q4 2025 adjusted loss was 14 cents per share, better than the expected loss of 19 cents, and an improvement from a loss of 28 cents in the same quarter last year [3]. - Operating revenues for Q4 2025 increased by 0.3% year over year to $642.3 million, surpassing the Zacks Consensus Estimate by 1.3% [3]. - For the full year 2025, operating revenues declined by 1.5% to $2.5 billion, while total expenses fell by 22.2% to $2.8 billion [5]. Segment Performance - Integrated Care segment revenues rose by 5% year over year to $409.1 million, exceeding estimates [9]. - BetterHelp segment revenues decreased by 6% year over year to $229.1 million, missing estimates [10]. - International revenues grew by 19% year over year to $125 million, outperforming expectations [7]. Operational Metrics - Total visits to Teladoc Health were 4.3 million in Q4, down 1% year over year, missing estimates [12]. - U.S. Integrated Care members increased by 9% year over year to 101.8 million, although slightly below consensus [12]. Cash Flow and Balance Sheet - As of December 31, 2025, cash and cash equivalents were $781.1 million, down from $1.3 billion at the end of 2024 [13]. - Net cash from operations for 2025 was $294.4 million, flat year over year, while free cash flow decreased by 2% to $166.9 million [14]. Future Outlook - For Q1 2026, total revenues are expected to be between $598 million and $620 million, with an adjusted EBITDA forecasted between $50 million and $62 million [16]. - For the full year 2026, revenues are projected to be in the range of $2.470 billion to $2.587 billion, with an adjusted EBITDA of $266 million to $308 million [18]. Market Sentiment - Since the earnings release, there has been a downward trend in consensus estimates, with a shift of -9.21% [19]. - Teladoc currently holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [21].